Denali Therapeutics Inc. (DNLI): Cash & Equivalents
$205.33M
As of 2025-12-31
$201.53M
As of 2026-06-30
-2.0%
3-year compound annual growth
-16.5%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $205.33M | +17.4% | 2026-02-26, Balance as of period end |
| 2024-12-31 | $174.96M | +37.6% | 2026-02-26, Balance as of period end |
| 2023-12-31 | $127.11M | -41.7% | 2025-02-27, Balance as of period end |
| 2022-12-31 | $218.04M | -25.7% | 2024-02-28, Balance as of period end |
| 2021-12-31 | $293.48M | -42.1% | 2023-02-27, Balance as of period end |
| 2020-12-31 | $507.14M | +538.3% | 2022-02-28, Balance as of period end |
| 2019-12-31 | $79.45M | +3.0% | 2021-02-26, Balance as of period end |
| 2018-12-31 | $77.12M | -64.7% | 2020-02-27, Balance as of period end |
| 2017-12-31 | $218.38M | +448.0% | 2020-02-27, Balance as of period end |
| 2016-12-31 | $39.85M | n/a | 2019-03-12, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Denali Therapeutics Inc. (DNLI) | 2025-12-31 | $205.33M | +17.4% |
| Amgen Inc (AMGN) | 2025-12-31 | $9.13B | -23.8% |
| Repligen Corp (RGEN) | 2025-12-31 | $566.02M | -25.3% |
| Bio-Techne Corp (TECH) | 2026-06-30 | $264.71M | +63.2% |
| Lineage Cell Therapeutics, Inc. (LCTX) | 2025-12-31 | $40.79M | -10.9% |
| BioCryst Pharmaceuticals Inc (BCRX) | 2025-12-31 | $89.74M | -14.3% |
| Vericel Corp (VCEL) | 2025-12-31 | $100.09M | +34.3% |
| Neurocrine Biosciences Inc (NBIX) | 2025-12-31 | $713.00M | +206.0% |
| Exelixis, Inc. (EXEL) | 2026-01-02 | $482.49M | +122.0% |
Compare DNLI, AMGN, RGEN, TECH side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗